Mucormycosis -a) Angio-invasionb) Lymph invasionc) Septate hyphaed) Long term deferoxamine therapy is predisposing factore) It may lead to blindness
## **Core Concept**
Mucormycosis, previously known as zygomycosis, is a serious but rare fungal infection caused by a group of molds called mucormycetes. It primarily affects individuals with compromised immune systems. The infection is characterized by its tendency to invade blood vessels, leading to tissue necrosis.
## **Why the Correct Answer is Right**
The correct answer involves understanding the key features of mucormycosis:
- **Angio-invasion (a)**: Mucormycosis is known for its angio-invasive properties. The fungi invade blood vessels, leading to thrombosis, tissue necrosis, and potentially life-threatening complications.
- **Long term deferoxamine therapy is predisposing factor (d)**: Deferoxamine, an iron-chelating agent, can increase the risk of mucormycosis, particularly in patients with iron overload. The fungi require iron to grow, and deferoxamine can inadvertently provide them with the necessary iron.
- **It may lead to blindness (e)**: Due to its angio-invasive nature, mucormycosis can affect the blood vessels supplying the eyes, potentially leading to blindness.
## **Why Each Wrong Option is Incorrect**
- **Option B: Lymph invasion**: Mucormycosis is characterized by its angio-invasive properties rather than lymph invasion. The primary mode of spread and tissue damage is through blood vessels.
- **Option C: Septate hyphae**: Mucormycetes, the causative agents of mucormycosis, have non-septate (or pauciseptate) hyphae. This distinguishes them from other fungi like Aspergillus, which has septate hyphae.
## **Clinical Pearl / High-Yield Fact**
A critical clinical pearl is that mucormycosis often presents with **rhinocerebral** involvement, especially in diabetic or immunocompromised patients. Early suspicion and aggressive treatment, including antifungal therapy and surgical debridement, are crucial for improving outcomes.
## **Correct Answer: D. a, d, e.**